Efficacy and Safety of Lebrikizumab is Maintained to Two Years in Patients with Moderate-to-Severe Atopic Dermatitis

Emma Guttman-Yassky,Stephan Weidinger,Eric Simpson,Melinda Gooderham,Alan Irvine,Lynda Spelman,Jonathan Silverberg,Hany Elmaraghy, Louise DeLuca-Carter,Maria Lucia Buziqui Piruzeli,Chaoran Hu,Fan Emily Yang,Evangeline Pierce,Laia Bardolet,Diamant Thaci

BRITISH JOURNAL OF DERMATOLOGY（2024）

引用 0|浏览27

暂无评分

关键词

atopic dermatitis,efficacy,lebrikizumab,phase 3 trials,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要